Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for IDEAYA Biosciences (IDYA) over the last 5 years, with Q4 2025 value amounting to $88.5 million.

  • IDEAYA Biosciences' Shares Outstanding (Diluted Average) rose 833.41% to $88.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $88.5 million, marking a year-over-year increase of 833.41%. This contributed to the annual value of $88.5 million for FY2025, which is 833.41% up from last year.
  • As of Q4 2025, IDEAYA Biosciences' Shares Outstanding (Diluted Average) stood at $88.5 million, which was up 833.41% from $88.5 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Shares Outstanding (Diluted Average) high stood at $88.5 million for Q4 2025, and its period low was $35.3 million during Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $67.6 million (2023), whereas its average is $66.2 million.
  • In the last 5 years, IDEAYA Biosciences' Shares Outstanding (Diluted Average) soared by 5527.88% in 2024 and then surged by 833.41% in 2025.
  • Over the past 5 years, IDEAYA Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $35.3 million in 2021, then rose by 17.57% to $41.4 million in 2022, then skyrocketed by 38.79% to $57.5 million in 2023, then surged by 42.0% to $81.7 million in 2024, then increased by 8.33% to $88.5 million in 2025.
  • Its last three reported values are $88.5 million in Q4 2025, $88.5 million for Q2 2025, and $88.4 million during Q1 2025.